Zenas BioPharma appoints Orlando Oliveira as Chief Commercial Officer to drive obexelimab growth.

Zenas BioPharma, an immunology-based therapy company, has appointed Orlando Oliveira as Chief Commercial Officer. Oliveira brings 25 years of experience in the biotech and pharma industry, with a record of building global commercial teams and driving revenue growth. His appointment aims to accelerate the obexelimab franchise and support Zenas' goal to bring obexelimab to patients worldwide.